A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

Inclusion Criteria: All Subjects * Healthy male and/or female of non childbearing potential subjects between the ages of 18 and 65 years, inclusive ('healthy' is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG, and clinical laboratory tests). * Body Mass Index (BMI) of 18 to 40 kg/m2 inclusive; and a total body weight \>50 kg (\>110 lbs). Subjects with Normal Renal Function (Group 1) * Normal renal function (CLcr =\>90 mL/min) during the screening period. * Matched 1-to-1 to subjects in Group 2 with respect to age (+/-5 years), weight (+/-10 kg), gender, and race according to protocol. Subjects with Severe Renal Impairment (Groups 2) * Good general health commensurate with the population with chronic kidney disease. * Severe renal impairment (CLcr\<30 mL/min) during the screening period. Exclusion Criteria: All Subjects * Renal allograft recipients. * Any condition possibly affecting drug absorption. * 12 lead ECG demonstrating QTc \>470 msec at screening. * Urinary incontinence without catheterization. * A positive urine drug screen. * History of regular alcohol consumption. * Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half lives preceding the first dose of study medication. * Pregnant or nursing females; females of childbearing potential, including those with tubal ligation. * Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing. Subjects with Severe Renal Impairment (Groups 2) * Subjects with any significant hepatic, cardiac or pulmonary disease (apart from stable ischemic heart disease), or subjects who are clinically nephrotic. * Subjects requiring hemodialysis. * Subjects with strict fluid restriction (ie, \<1500 mL/24 hours). * Significant bleeding diathesis which could preclude multiple venipuncture. * Use of food or drugs that are CYP3A4 inhibitors and inducers. * Herbal supplements and hormone replacement therapy must be discontinued 28 days prior to the first dose of trial medication * Concurrent use of drugs that are CYP3A4 substrates with narrow therapeutic indices.